After the U.S. Food and Drug Administration recently approved an investigational new drug application for Anavex 2-73, Anavex Life Sciences is proceeding with its Phase 2 clinical trial of the medication in Rett syndrome patients, the company announced. The trial (NCT03758924) will assess the safety, tolerability,…
News
Recent Posts
- A casual chat about Rett syndrome, then a surprise in the mail
- Blocking cellular stress protein may help ease Rett symptoms
- My daughter with Rett syndrome will never ride Medusa — and neither will I
- Learning to view mobility aids and other medical equipment as vital tools
- Daybu wins approval in EU as region’s first Rett syndrome treatment
- Rett syndrome as a windowless warehouse, and my daughter inside
- Neurogene gearing up to apply for approval of Rett gene therapy
- The surgery for scoliosis that went frighteningly awry, Part 3
- Partners team up to test Rett syndrome treatment in primates
- The surgery for scoliosis that went frighteningly awry, Part 2